Search Results

A phase 1 study of DR-0201, a bispecific myeloid engager, in patients with B-NHL

In November 2022, LLS made an equity investment in Dren Bio to "Support Clinical Development of the DR-01 Program for Rare Leukemia & Lymphoma Indications Including Large Granular Lymphocyte Leukemia (LGLL) and Cytotoxic Lymphomas."

A phase 2 expansion study of ICT01, an anti-BTN3A monoclonal antibody, in combination with azacitidine and venetoclax in patients with AML

In June 2022, LLS made an equity investment in ImCheck Therapeutics to "Support Clinical Development of the ICT01 Program for Blood Cancer Indications." ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

Therapy Acceleration Program - Portfolio

Since 2017, three TAP-supported therapies have been approved by the U.S.

Developing Novel CAR-T Cell Therapy For Hematologic Malignancies

We observed that patients with many hematologic cancers expressed high levels of DKK1 and generated novel human DKK1-A2 CAR-T cells that can kill cancer cells from HLA-A2+ patients with myeloma, lymphoma, or leukemia. We also found that Th9-polarized T cells have enhanced antitumor effects in vivo. In this proposal, we will determine 1) whether and how Th9-polarized DKK1-A2 CAR-T cells are promising effector T cells for immunotherapy of human patients, and 2) whether Th9-polarized DKK1-A2 CAR-T cells are associated with reduced on- and off-target toxicities.

A phase 2 study of Bexmarilimab, an anti-Clever1 monoclonal antibody, in combination with azacitidine in patients with high-risk MDS

In June 2022, LLS made an equity investment in Faron Pharmaceuticals to "Support Clinical Development of the Bexmarilimab Program for Leukemia Indications." Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. 

The Immune Niche in the Development of Hematological Malignancies and Implications for Novel Therapy

Our SCOR Program, composed of four complementary Projects supported by three shared Cores, is designed to determine how the immune niche and factors in its composition and regulation affect the initiation and progression of hematopoietic malignancies. Using genetically engineered mouse models, cell cultures and patient samples, the power of multi-omics analyses will be brought to bear to identify common drivers and expose underlying mechanisms.

Novel CD7 CAR T-cells for refractory T-cell malignancies affecting pediatric and AYA patients

T-cell leukemias and lymphomas have devastating outcomes if they recur after or don’t respond to standard treatment, with the only hope of cure being bone marrow transplant (BMT). Unfortunately, many pediatric, adolescent and young adult (AYA) patients are unable to achieve clinical remission (and thus unable to proceed to BMT) with standard salvage therapies, which are often even more toxic than upfront therapies.

A phase 2 registration-directed clinical study of ziftomenib (KO-539), a menin inhibitor, in patients with NPM1-mutant relapsed or refractory AML

Starting in July 2010, LLS TAP supported a promising University of Michigan research project led by <a href="https://www.lls.org/award-recipient/jolanta-grembecka" target="_blank">Jolanta Grembecka, PhD</a>, to develop new treatments for patients with a rare and lethal subtype of leukemia. Through TAP, LLS engaged chemists to improve the properties that produced lead compounds that exhibited potent anti-leukemic activity.

Pharmacological strategies to enhance T- and NK-cell-based therapies in blood cancers

Although they represent a major therapeutic progress for blood cancers, CAR-T cells and other T-cell based therapies are subject to eventual development of resistance to many patients. Natural killer (NK) cell-based therapies are highly active against many types of blood cancer cells which are resistant to T cells, but in our CRISPR studies death receptor signaling defects emerge as a common downstream mechanism of resistance to both T- and NK-cell therapies.

A phase 2 study of RVU120, a novel CDK8 inhibitor, in genetically defined cohorts of patients with AML and high-risk MDS

In August 2017, LLS TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase 1b Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome." Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology using a proprietary discovery engine platform.

A phase 2 study of RVU120, a novel CDK8 inhibitor, in combination with venetoclax in patients with AML

A phase 2 study of RVU120, a novel CDK8 inhibitor, in patients with low-risk MDS

A phase 2 study of RVU120, a novel CDK8 inhibitor, in patients with myelofibrosis

Targeting mutated MYD88 pro-survival signaling in B-cell malignancies

Our laboratory and those of others discovered highly recurring mutations in the gene MYD88 which are found in patients with various B-cell cancers including Waldenstrom’s Macroglobulinemia (95-97%), ABC Subtype of Diffuse B-cell Lymphoma (30-40%), Primary Central Nervous Lymphoma (80%), Marginal Zone Lymphoma (10%) and Chronic Lymphocytic Leukemia (5-10%).

KT1, a novel NK trispecific antibody for the treatment of AML and MDS

New treatments for AML and MDS are urgently needed. We have developed and performed preliminary testing of a novel, patent-protected, trispecific NK cell engager named KT1 which targets AML blasts and leukemia stem cells (LSCs) expressing CD33 and CD123 for elimination by effector cells that express CD16a/b.

Financial and Legal

Balancing Work

The many responsibilities of caring for someone often leads to job conflicts. Work is a financial necessity and a major source of personal satisfaction, but for many caregivers, it is often difficult to balance the twin responsibilities of caregiving and working. Each caregiver’s working conditions are different. Talk to your supervisor and look in the employee handbook or other human resources publications to learn about your company’s policy on caregivers.

Epigenetic Mechanisms and Targeting in Hematological Malignancy

Blood cancers can be caused by aberrant regulation of genes that control cell growth and development. The root cause of this problem may be the presence of mutant regulator proteins in the cell and abnormal switching on or off of target genes. Our SCOR studies the molecular basis of this gene deregulation using cell cultured in the laboratory, in human specimen and animal models.

Understanding Blood Cancers and Treatment Options

Leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the bone marrow, blood cells, lymph nodes and other parts of the lymphatic system. See the Disease Information pages to learn more about the different types of blood cancer.

Nutrition

Food provides valuable nutrients for cancer patients. Eating well during cancer treatment helps to speed recovery, ease side effects, and keep the treatment plan running smoothly.

Asistencia Financiera Local

¿TIENES DEUDA MEDICA? ES POSIBLE QUE LLS PUEDA AYUDARHaga clic aquí para obtener más información

Related Diseases

Chronic lymphocytic leukemia (CLL) shares some similar features and symptoms with other closely related types of leukemia.

Izabella

When I was twelve years old, I was diagnosed with a very rare type of leukemia found in children. I was life-flighted, had various treatments and procedures, and even had four blood transfusions. As incredibly shocking and terrifying as it all was, I pulled through in only a week of treatment. My type of leukemia is called chronic myeloid leukemia (CML). This leukemia is something that will be a part of me forever. Even still, I take a daily oral chemotherapy pill. Despite all of this, I maintain my path in life and will not let anything stop me.

Sherri

I lost my dad to leukemia 20 years ago, fundraising all year in his honor for the year he knew about his diagnosis but didn’t tell anyone. We also lost his mom (grandma) to leukemia in 2002 and my mother-in-law in 2007 to leukemia. I proudly support The Leukemia & Lymphoma Society (LLS) and try to donate every year, but this year, I hope to donate a big chunk to help current patients and their families.

Clinical Trials

Taking part in a clinical trial may be a treatment choice for some hairy cell leukemia patients. Clinical trials are under way to develop treatments that increase the remission rate of hairy cell leukemia or cure the disease. Today's standard treatments for cancer are based on earlier clinical trials. The Leukemia & Lymphoma Society continues to invest funds in hairy cell leukemia research.

Treatment

It's important that your doctor is experienced in treating patients with hairy cell leukemia or works in consultation with a hairy cell leukemia specialist. This type of specialist is usually called a hematologist oncologist.

Types of Hairy Cell Leukemia Treatment

For many people with hairy cell leukemia, starting treatment helps them focus on moving ahead and looking forward to their disease's remission.

Several types of approaches and treatment are used for adults with hairy cell leukemia, some at different stages: